Moderna Stock Analysis

MRNA -  USA Stock  

USD 348.83  25.35  7.84%

The current price rise of Moderna may encourage investors to take a closer look at the firm as it is trading at a share price of 348.83 on 23,404,800 in trading volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in August. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.7. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Moderna partners.
Additionally, see Stocks Correlation.

Search Stock Analysis 

 
Refresh
The Moderna stock analysis report makes it easy to digest most publicly released information about Moderna and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Moderna Stock analysis module also helps to analyze the Moderna price relationship with some important fundamental indicators such as market cap and management efficiency.

Moderna Stock Analysis Notes

About 54.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.43. Moderna had not issued any dividends in recent years. The entity had 1:10 split on the 3rd of August 2017. Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1300 people. To find out more about Moderna contact Michael French at 617 714 6500 or learn more at http://www.modernatx.com.

Moderna Quarterly Cost of Revenue

193 MillionShare

Moderna Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Moderna's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Moderna or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Moderna appears to be risky and price may revert if volatility continues
Moderna has a poor financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Exercise or conversion by Andres Juan of 5000 shares of Moderna subject to Rule 16b-3

Moderna Upcoming and Recent Events

Earnings reports are used by Moderna to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Moderna previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Moderna Largest EPS Surprises

Earnings surprises can significantly impact Moderna's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-02-26
2019-12-31-0.4215-0.370.051512 
2020-08-05
2020-06-30-0.363-0.310.05314 
2019-11-06
2019-09-30-0.4386-0.370.068615 
View All Earnings Estimates

Moderna SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Moderna prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Moderna investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Moderna specific information freely available to individual and institutional investors to make a timely investment decision.
12th of July 2021
Unclassified Corporate Event
View
6th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
29th of April 2021
Submission of Matters to a Vote of Security Holders
View
28th of April 2021
Other Events
View
13th of April 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
10th of March 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
1st of March 2021
Unclassified Corporate Event
View
25th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Moderna Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Moderna is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Moderna backward and forwards among themselves. Moderna's institutional investor refers to the entity that pools money to purchase Moderna's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vaughan Nelson Investment Management LpCommon Shares950.4 K223.3 M
Candriam Luxembourg ScaCommon Shares307 K72.1 M
Bank Julius Baer Co Ltd ZurichCommon Shares269.7 K63.4 M
State Of New Jersey Common Pension Fund DCommon Shares188.3 K44.2 M
Royal London Asset Management LtdCommon Shares121.7 K28.6 M
Heathbridge Capital Management LtdCommon Shares120.8 K28.4 M
Oregon Public Employees Retirement FundCommon Shares112.1 K26.4 M
Note, although Moderna's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Moderna Market Capitalization

The company currently falls under 'Mega-Cap' category with current market capitalization of 140.07 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Moderna's market, we take the total number of its shares issued and multiply it by Moderna's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Moderna Profitablity

Moderna's profitability indicators refer to fundamental financial ratios that showcase Moderna's ability to generate income relative to its revenue or operating costs. If, let's say, Moderna is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Moderna's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Moderna's profitability requires more research than a typical breakdown of Moderna's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 21.88 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 23.2 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.23.
Last ReportedProjected for 2021
Return on Average Assets(0.17) (0.18) 
Return on Average Equity(0.30) (0.33) 
Return on Invested Capital(0.51) (0.55) 
Return on Sales(0.93) (1.00) 

Management Efficiency

The entity has return on total asset (ROA) of 5.37 % which means that it generated profit of $5.37 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 21.83 %, meaning that it created $21.83 on every $100 dollars invested by stockholders. Moderna management efficiency ratios could be used to measure how well moderna manages its routine affairs as well as how well it operates its assets and liabilities. As of July 24, 2021, Return on Average Assets is expected to decline to -0.18. In addition to that, Return on Average Equity is expected to decline to -0.33. Moderna Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 7.34 Billion. The current year Current Assets is expected to grow to about 6.8 B, whereas Assets Non Current are forecasted to decline to about 839.8 M.
Last ReportedProjected for 2021
Book Value per Share 6.72  7.25 
Enterprise Value over EBIT(54.00) (55.42) 
Enterprise Value over EBITDA(61.51) (63.13) 
Price to Book Value 16.14  13.31 
Tangible Assets Book Value per Share 19.24  17.57 
Enterprise Value40 B43.2 B
Tangible Asset Value7.3 B7.9 B

Technical Drivers

As of the 24th of July, Moderna secures the Downside Deviation of 2.91, risk adjusted performance of 0.2453, and Mean Deviation of 3.0. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Moderna, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Moderna, which can be compared to its peers in the industry. Please verify Moderna coefficient of variation, maximum drawdown, skewness, as well as the relationship between the information ratio and downside variance to decide if Moderna is priced some-what accurately, providing market reflects its recent price of 348.83 per share. Given that Moderna has jensen alpha of 1.15, we recommend you to check Moderna's last-minute market performance to make sure the company can sustain itself at a future point.

Moderna Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Moderna Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Moderna insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Andres Juan a day ago via Macroaxis 
Exercise or conversion by Andres Juan of 5000 shares of Moderna subject to Rule 16b-3
Andres Juan few days ago via Macroaxis 
Exercise or conversion by Andres Juan of 10000 shares of Moderna subject to Rule 16b-3
Andres Juan over two weeks ago via Macroaxis 
Exercise or conversion by Andres Juan of 5000 shares of Moderna subject to Rule 16b-3
Andres Juan over two weeks ago via Macroaxis 
Exercise or conversion by Andres Juan of 5000 shares of Moderna subject to Rule 16b-3
Andres Juan over three weeks ago via Macroaxis 
Exercise or conversion by Andres Juan of 5000 shares of Moderna subject to Rule 16b-3
Andres Juan over three weeks ago via Macroaxis 
Exercise or conversion by Andres Juan of 5000 shares of Moderna subject to Rule 16b-3
Andres Juan over a month ago via Macroaxis 
Exercise or conversion by Andres Juan of 5000 shares of Moderna subject to Rule 16b-3
Andres Juan over a month ago via Macroaxis 
Exercise or conversion by Andres Juan of 5000 shares of Moderna subject to Rule 16b-3
Andres Juan over a month ago via Macroaxis 
Exercise or conversion by Andres Juan of 5000 shares of Moderna subject to Rule 16b-3
Klinger Shannon Thyme over a month ago via Macroaxis 
Acquisition by Klinger Shannon Thyme of 9108 shares of Moderna subject to Rule 16b-3
Hoge Stephen over a month ago via Macroaxis 
Exercise or conversion by Hoge Stephen of 10000 shares of Moderna subject to Rule 16b-3
Andres Juan over a month ago via Macroaxis 
Exercise or conversion by Andres Juan of 5000 shares of Moderna subject to Rule 16b-3

Moderna Predictive Daily Indicators

Moderna intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Moderna stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Moderna Forecast Models

Moderna time-series forecasting models is one of many Moderna's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Moderna's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Moderna Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Moderna stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Moderna shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Moderna. By using and applying Moderna Stock analysis, traders can create a robust methodology for identifying Moderna entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(0.81) (0.87) 
Gross Margin 0.99  0.94 
Profit Margin(0.93) (1.01) 
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1300 people.

Current Moderna Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Moderna analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Moderna analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
170.18Hold11Odds
Moderna current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Moderna analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Moderna stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Moderna, talking to its executives and customers, or listening to Moderna conference calls.
Moderna Analyst Advice Details

Moderna Stock Analysis Indicators

Moderna stock analysis indicators help investors evaluate how Moderna stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Moderna shares will generate the highest return on investment. By understating and applying Moderna stock analysis, traders can identify Moderna position entry and exit signals to maximize returns.
Quick Ratio1.30
Fifty Two Week Low54.21
Revenue Growth24,112.50%
Shares Short Prior Month12.94M
Average Daily Volume Last 10 Day34.51M
Average Daily Volume In Three Month12.32M
Shares Percent Shares Out2.95%
Gross Margins32.03%
Short Percent Of Float4.03%
Forward Price Earnings19.17
Float Shares342.11M
Fifty Two Week High349.41
Enterprise Value To Ebitda120.97
Fifty Day Average234.08
Two Hundred Day Average172.81
Enterprise Value To Revenue29.80
Additionally, see Stocks Correlation. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.